Red blood substitute (Q107912): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed an Item: Fixing rounding issue)
(‎Removed claim: summary (P836): The project involves the development of R & D in order to develop a safe substitute for red blood cells, so called ‘artificial blood’ for therapeutic uses in humans. Currently, this product type is not offered on the domestic market, as well as in the European and US markets. This is evidenced by the highly innovative nature of the solution being developed. In view of the increasing demand for blood and its components and the limitations of na...)
Property / summary
The project involves the development of R & D in order to develop a safe substitute for red blood cells, so called ‘artificial blood’ for therapeutic uses in humans. Currently, this product type is not offered on the domestic market, as well as in the European and US markets. This is evidenced by the highly innovative nature of the solution being developed. In view of the increasing demand for blood and its components and the limitations of national blood donation and Blood Systems, there is an urgent need for the project’s results, contributing to improving health and saving many lives. The target group of the project is the medical personnel (doctors and nurses) and all humans who, when carrying out medical procedures, require transfusion of blood. The product developed will be able to be used by persons who, for philosophical and religious reasons, refuse treatment with human blood or products containing zoonoses. Large pharmaceutical companies are also part of the target audience, interested in purchasing licences. The project involves carrying out 1 stages of industrial research and 2 stages of experimental development. Industrial research will be carried out by the Applicant on its own, with qualified and experienced research and management staff and technical resources (laboratory facilities and testing equipment). In the implementation phase 1 of the development phase, a subcontractor selected by the applicant will be involved, which is responsible, inter alia, for carrying out the pre-clinical tests of the preparation for a small and large animal model. External experts will also be involved so that the project will be based on user-centred design. In order to protect the intellectual property generated by the project, a patent application is planned. The project will be implemented in accordance with the principles of energy saving and efficient use of natural resources. (English)
 
Property / summary: The project involves the development of R & D in order to develop a safe substitute for red blood cells, so called ‘artificial blood’ for therapeutic uses in humans. Currently, this product type is not offered on the domestic market, as well as in the European and US markets. This is evidenced by the highly innovative nature of the solution being developed. In view of the increasing demand for blood and its components and the limitations of national blood donation and Blood Systems, there is an urgent need for the project’s results, contributing to improving health and saving many lives. The target group of the project is the medical personnel (doctors and nurses) and all humans who, when carrying out medical procedures, require transfusion of blood. The product developed will be able to be used by persons who, for philosophical and religious reasons, refuse treatment with human blood or products containing zoonoses. Large pharmaceutical companies are also part of the target audience, interested in purchasing licences. The project involves carrying out 1 stages of industrial research and 2 stages of experimental development. Industrial research will be carried out by the Applicant on its own, with qualified and experienced research and management staff and technical resources (laboratory facilities and testing equipment). In the implementation phase 1 of the development phase, a subcontractor selected by the applicant will be involved, which is responsible, inter alia, for carrying out the pre-clinical tests of the preparation for a small and large animal model. External experts will also be involved so that the project will be based on user-centred design. In order to protect the intellectual property generated by the project, a patent application is planned. The project will be implemented in accordance with the principles of energy saving and efficient use of natural resources. (English) / rank
Normal rank
 

Revision as of 17:15, 17 October 2020

Project in Poland financed by DG Regio
Language Label Description Also known as
English
Red blood substitute
Project in Poland financed by DG Regio

    Statements

    country
    Poland
    0 references
    EU contribution
    1,735,346.59 zloty
    0 references
    416,483.18 Euro
    exchange rate to Euro
    0.24 Euro
    point in time
    13 January 2020
    0 references
    budget
    2,609,028.33 zloty
    0 references
    626,166.8 Euro
    exchange rate to Euro
    0.24 Euro
    point in time
    13 January 2020
    0 references
    co-financing rate
    66.51 percent
    0 references
    start time
    1 September 2016
    0 references
    end time
    31 December 2019
    0 references
    beneficiary name (string)
    NANOSANGUIS SPÓŁKA AKCYJNA
    0 references
    beneficiary
    Q2509661
    0 references
    coordinate location

    52°14'1.3"N, 21°4'17.0"E
    0 references
    summary
    Przedmiotem projektu jest przeprowadzenie prac B+R, w celu opracowania bezpiecznego substytutu czerwonych krwinek, tzw. „sztucznej krwi”, do zastosowań terapeutycznych u ludzi. Obecnie tego typu produkt nie jest oferowany na rynku krajowym, a także europejskim i w USA. Powyższe świadczy o wysokiej innowacyjności opracowywanego rozwiązania. W związku z rosnącym popytem na krew i jej składniki i ograniczeniami krajowych systemów krwiodawstwa i krwiolecznictwa, odnotowywane jest pilne zapotrzebowania na rezultaty projektu, przyczyniące się do poprawy zdrowia i uratowania wielu ludzkich istnień. Grupę docelową projektu stanowi personel medyczny (lekarze i pielęgniarki) i wszyscy ludzie, którzy przy wykonywaniu zabiegów medycznych wymagają transfuzji krwi. Opracowany produkt będzie mógł być stosowany przez osoby, które ze względów światopoglądowych i religijnych, odmawiają leczenia z wykorzystaniem krwi ludzkiej, bądź produktów zawierających składniki odzwierzęce. Do grupy odbiorców zaliczają się też duże firmy farmaceutyczne, zainteresowane zakupem licencji. Projekt obejmuje przeprowadzenie 1 etapu badań przemysłowych i 2 etapów eksperymentalnych prac rozwojowych. Badania przemysłowe realizowane będą samodzielnie przez Wnioskodawcę, dysponującego wykwalifikowaną i doświadczoną kadrą badawczą i zarządzającą i zasobami technicznymi (pomieszczenia laboratoryjne i sprzęt badawczy). W realizację 1 etapu prac rozwojowych zaangażowany zostanie wyłoniony przez Wnioskodawcę podwykonawca, odpowiedzialny m. in. za przeprowadzenie badań przedklinicznych preparatu na małym i dużym modelu zwierzęcym. Zaangażowani zostaną też zewnętrzni eksperci, dzięki czemu projekt realizowany będzie w oparciu o metody projektowania zorientowanego na użytkownika. W celu ochrony własności intelektualnej powstałej w projekcie, planowane jest dokonanie zgłoszenia patentowego. Projekt realizowany będzie zgodnie z zasadami oszczędności energii i efektywnego wykorzystania zasobów naturalnych. (Polish)
    0 references

    Identifiers

    Polish Kohesio ID
    RPMA.01.02.00-14-5721/16
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q107912&oldid=6432671"